Developer docs
API playgroundTry for free, no card

Search company profiles

Emeritus Research

Full company profile

uuid000f9it

Namestring
Emeritus Research
Legal namestring
Emeritus Research Pty Ltd
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Emeritus Research is an Australian Phase I–IV outpatient clinical trial site services provider headquartered in Camberwell, Melbourne, with a second purpose-built facility in Sydney (Botany). Founded in 1999, the company conducts clinical trials for pharmaceutical sponsors and Contract Research Organizations (CROs) across more than 30 therapeutic areas, including infectious disease and vaccines (150+ studies), obesity and metabolic disease (24+ studies in five years), dermatology (50+ studies), rheumatology, cardiovascular, sexual health, and neurology. The company reports over 250 trials conducted and 8,000+ participants enrolled across both sites.

The underlying technology stack consists of a proprietary Clinical Trial Management System (CTMS) that supports operational tracking and enables 24-hour data entry across 98% of trials, alongside an exclusive partnership with Clinibase, a sister company described as Australia's largest full-service clinical trial recruitment provider. Clinibase delivers targeted digital recruitment campaigns with rigorous pre-screening. Emeritus also operates a dedicated investigator bench, including a world-leading rheumatologist CMO (Professor Paul Bird) and multiple Principal Investigators with specialty credentials spanning first-in-human, vaccine, dermatology, and metabolic disease trials.

The business model is professional services: revenue is generated through contracted clinical trial site services with pharmaceutical sponsors and CROs, with fees negotiated on a per-study basis and structured as per-patient costs, fixed site fees, or milestone-based payments. Go-to-market is primarily enterprise field sales via a dedicated Business Development team, targeting global big-pharma and biotech sponsors seeking Australian trial sites. Customer base includes 14+ named blue-chip pharmaceutical logos (Sanofi, GSK, J&J, Pfizer, Roche, Novartis, Eli Lilly, BMS, Gilead, Merck MSD, Amgen, Janssen, UCB, Celgene). The company is privately held under Emeritus Research Pty Ltd with no disclosed institutional funding or parent company.

Short descriptiontext

Emeritus Research is a privately held Australian clinical trial site operator running Phase I–IV outpatient trials in Melbourne and Sydney for global pharmaceutical sponsors and CROs across 30+ therapeutic areas, including vaccines, obesity, and dermatology, supported by an exclusive recruitment partnership with Clinibase.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCamberwell, Australia
HQ citystring
Camberwell
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial services, Phase I-IV trials, vaccine research, patient recruitment, therapeutic area research
Industry3 codes
PRIMARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
SECONDARYHLAGACAG
Clinical Trial Monitoring Support (On-site/Remote)
SECONDARYHLAGACAK
Clinical Trial Pharmacy & IMP Management at Site
NAICS code2 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Clinical Trial Site Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Trial Site Services
TypeProfessional Services
Description

Emeritus Research generates revenue by providing clinical trial site services to pharmaceutical sponsors and CROs. Services include conducting Phase I-IV outpatient clinical trials across multiple therapeutic areas, participant recruitment (via exclusive partnership with Clinibase), data management, and regulatory support. Revenue is earned through contracted clinical research services with fees typically structured as per-patient costs, fixed site fees, or milestone-based payments depending on study complexity and sponsor agreements.

emeritusresearch.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Emeritus Research is a private clinical trial site services organization that conducts Phase I-IV outpatient clinical trials for pharmaceutical sponsors and CROs across purpose-built facilities in Melbourne and Sydney, Australia. The company delivers full-service trial management, participant recruitment (via exclusive partnership with Clinibase), data management, and regulatory support across 30+ therapeutic areas including infectious disease, vaccines, obesity/metabolic diseases, rheumatology, cardiovascular, dermatology/immunology, neurology, and sexual health.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 98% of trials have 24-hour data entry turnaround
+6 more records
Product overview1 text field

Emeritus Research operates as a single unified clinical research organization offering comprehensive Phase I–IV trial services across multiple therapeutic areas. The core offering consists of full-service clinical trial management delivered through purpose-built sites in Melbourne and Sydney, supported by an exclusive partnership with Clinibase for patient recruitment. The portfolio spans specialized research services across seven therapeutic areas: Vaccine Research (150+ studies), Metabolic Disease/Obesity (24+ trials), Sexual Health, Rheumatology, Cardiovascular, Dermatology/Immunology (50+ studies), and Neurology. The company differentiates through experienced investigators, rapid 24-hour data entry, and high participant retention rates (98% completion, 90%+ in obesity studies), providing biotech and pharma sponsors with a single trusted partner for Australian clinical development programs.

Product and service2 records
1Clinical Trial Services (Phase I-IV)
CategoryClinical Trial Site Services
Description

Full-service clinical trial management delivering Phase I-IV outpatient trials from purpose-built sites in Melbourne and Sydney, combining experienced investigators with rapid 24-hour data entry across 98% of trials. Designed for global pharmaceutical sponsors and CROs seeking to run clinical studies in Australia.

2Patient Recruitment Services
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive partnership with Clinibase, Australia's largest full service clinical trial recruitment provider and a sister company. Clinibase delivers large-scale, targeted digital recruitment campaigns designed to reach specific patient populations, with every lead carefully pre-screened before a clinic visit is booked. This ensures only well-qualified participants progress into studies. The partnership includes a seamless, sponsor-aligned pathway from first contact to first visit, with Clinibase functioning as the primary recruitment engine for Emeritus Research.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Brisbane-based early-phase clinical trial unit specializing in healthy volunteer studies, vaccine trials, and first-in-human research; competes head-to-head with Emeritus for sponsor allocations in Australia.

TypeOthers
Description

Preclinical and early-phase clinical research services provider including early-phase site operations; comparable as an adjacent player that competes for early-phase sponsor budgets and influences site selection strategy.

TypeDirect peer
Description

Perth-based Australian clinical trial site conducting Phase I-IV trials across multiple therapeutic areas; a direct competitor for sponsor placements in Australia and a comparable SMO with purpose-built facilities and early-phase capabilities.

TypeDirect peer
Description

Australia's largest early-phase clinical trial organization with dedicated Phase I units in Melbourne and Brisbane; directly comparable to Emeritus for first-in-human, vaccine, and early-phase biotech trials targeting Australian sites.

TypeDirect peer
Description

Adelaide-based Phase I-II clinical trial facility focused on early-phase and first-in-human studies; a regional Australian SMO competing for similar biotech and pharma sponsor workloads.

TypeDirect peer
Description

Australian multi-site clinical research organization running Phase I-IV trials with sites across multiple states; an emerging peer scaling head-to-head with Emeritus for sponsor placements in dermatology, vaccines, and metabolic indications.

TypeBroad incumbent
Description

Global CRO that owns dedicated clinical trial sites (e.g., PRA Health) and acts as a sponsor intermediary that books capacity at SMOs like Emeritus; comparable as a buyer-of-services and as a broader end-to-end alternative for sponsors.

TypeBroad incumbent
Description

World's largest CRO with embedded site network and site-management offerings; competes indirectly with Emeritus both as a buyer of SMO capacity in Australia and as an integrated alternative for sponsors.

TypeBroad incumbent
Description

Mid-to-large global CRO with strong biotech sponsor relationships that frequently engage Australian SMOs; relevant comparable as a counterparty and as an integrated alternative to using a dedicated Australian SMO.

TypeBroad incumbent
Description

Global CRO and clinical research services provider post-PPD acquisition; relevant as both a buyer of Emeritus's SMO capacity and as a broader competitive offering for sponsors running Australian trials.

Market position
Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers20 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Emeritus Research

Clinical Trial Site Servicesemeritusresearch.com

Emeritus Research is a privately held Australian clinical trial site operator running Phase I–IV outpatient trials in Melbourne and Sydney for global pharmaceutical sponsors and CROs across 30+ therapeutic areas, including vaccines, obesity, and dermatology, supported by an exclusive recruitment partnership with Clinibase.

What Emeritus Research does

Emeritus Research is an Australian Phase I–IV outpatient clinical trial site services provider headquartered in Camberwell, Melbourne, with a second purpose-built facility in Sydney (Botany). Founded in 1999, the company conducts clinical trials for pharmaceutical sponsors and Contract Research Organizations (CROs) across more than 30 therapeutic areas, including infectious disease and vaccines (150+ studies), obesity and metabolic disease (24+ studies in five years), dermatology (50+ studies), rheumatology, cardiovascular, sexual health, and neurology. The company reports over 250 trials conducted and 8,000+ participants enrolled across both sites.

The underlying technology stack consists of a proprietary Clinical Trial Management System (CTMS) that supports operational tracking and enables 24-hour data entry across 98% of trials, alongside an exclusive partnership with Clinibase, a sister company described as Australia's largest full-service clinical trial recruitment provider. Clinibase delivers targeted digital recruitment campaigns with rigorous pre-screening. Emeritus also operates a dedicated investigator bench, including a world-leading rheumatologist CMO (Professor Paul Bird) and multiple Principal Investigators with specialty credentials spanning first-in-human, vaccine, dermatology, and metabolic disease trials.

The business model is professional services: revenue is generated through contracted clinical trial site services with pharmaceutical sponsors and CROs, with fees negotiated on a per-study basis and structured as per-patient costs, fixed site fees, or milestone-based payments. Go-to-market is primarily enterprise field sales via a dedicated Business Development team, targeting global big-pharma and biotech sponsors seeking Australian trial sites. Customer base includes 14+ named blue-chip pharmaceutical logos (Sanofi, GSK, J&J, Pfizer, Roche, Novartis, Eli Lilly, BMS, Gilead, Merck MSD, Amgen, Janssen, UCB, Celgene). The company is privately held under Emeritus Research Pty Ltd with no disclosed institutional funding or parent company.

Emeritus Research firmographics

Firmographics
Name
Emeritus Research
Legal name
Emeritus Research Pty Ltd
Website
https://emeritusresearch.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
101–250 employees
Short description
Emeritus Research is a privately held Australian clinical trial site operator running Phase I–IV outpatient trials in Melbourne and Sydney for global pharmaceutical sponsors and CROs across 30+ therapeutic areas, including vaccines, obesity, and dermatology, supported by an exclusive recruitment partnership with Clinibase.
Ownership category
akta.pro rank

Emeritus Research industry classification

Industry
Product category
Clinical Trial Site Services
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical and Diagnostic Laboratories (6215)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
SECONDARYHLAGACAG
Clinical Trial Monitoring Support (On-site/Remote)
SECONDARYHLAGACAK
Clinical Trial Pharmacy & IMP Management at Site

Keywords

  • Clinical trial services
  • Phase I-IV trials
  • Vaccine research
  • Patient recruitment
  • Therapeutic area research

Where Emeritus Research is headquartered

Location

Headquarters

HQ city
Camberwell
HQ country
Australia
HQ region
Oceania

Offices2 records

Markets served

Emeritus Research business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

  1. Clinical Trial Site Services: Emeritus Research generates revenue by providing clinical trial site services to pharmaceutical sponsors and CROs. Services include conducting Phase I-IV outpatient clinical trials across multiple therapeutic areas, participant recruitment (via exclusive partnership with Clinibase), data management, and regulatory support. Revenue is earned through contracted clinical research services with fees typically structured as per-patient costs, fixed site fees, or milestone-based payments depending on study complexity and sponsor agreements.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Emeritus Research product offering

Product offering

Core offering

Emeritus Research is a private clinical trial site services organization that conducts Phase I-IV outpatient clinical trials for pharmaceutical sponsors and CROs across purpose-built facilities in Melbourne and Sydney, Australia. The company delivers full-service trial management, participant recruitment (via exclusive partnership with Clinibase), data management, and regulatory support across 30+ therapeutic areas including infectious disease, vaccines, obesity/metabolic diseases, rheumatology, cardiovascular, dermatology/immunology, neurology, and sexual health.

Product overview

Emeritus Research operates as a single unified clinical research organization offering comprehensive Phase I–IV trial services across multiple therapeutic areas. The core offering consists of full-service clinical trial management delivered through purpose-built sites in Melbourne and Sydney, supported by an exclusive partnership with Clinibase for patient recruitment. The portfolio spans specialized research services across seven therapeutic areas: Vaccine Research (150+ studies), Metabolic Disease/Obesity (24+ trials), Sexual Health, Rheumatology, Cardiovascular, Dermatology/Immunology (50+ studies), and Neurology. The company differentiates through experienced investigators, rapid 24-hour data entry, and high participant retention rates (98% completion, 90%+ in obesity studies), providing biotech and pharma sponsors with a single trusted partner for Australian clinical development programs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Clinical Trial Services (Phase I-IV) Full-service clinical trial management delivering Phase I-IV outpatient trials from purpose-built sites in Melbourne and Sydney, combining experienced investigators with rapid 24-hour data entry across 98% of trials. Designed for global pharmaceutical sponsors and CROs seeking to run clinical studies in Australia.
  • Patient Recruitment Services

Quantifiable outcome

  • 98% of trials have 24-hour data entry turnaround
  • +6 more outcomes

Companies that use Emeritus Research

Customer profile

Named customers20 records

Segments3 records

Ideal customer profiles2 records

Emeritus Research technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Emeritus Research partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ClinibasecoreChannel Partner/ Reseller/ DistributorExclusive partnership with Clinibase, Australia's largest full service clinical trial recruitment provider and a sister company. Clinibase delivers large-scale, targeted digital recruitment campaigns designed to reach specific patient populations, with every lead carefully pre-screened before a clinic visit is booked. This ensures only well-qualified participants progress into studies. The partnership includes a seamless, sponsor-aligned pathway from first contact to first visit, with Clinibase functioning as the primary recruitment engine for Emeritus Research.

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Emeritus Research competitors and assessment

Company assessment

Direct peers

  • Q-Pharm: Brisbane-based early-phase clinical trial unit specializing in healthy volunteer studies, vaccine trials, and first-in-human research; competes head-to-head with Emeritus for sponsor allocations in Australia.
  • Linear Clinical Research: Perth-based Australian clinical trial site conducting Phase I-IV trials across multiple therapeutic areas; a direct competitor for sponsor placements in Australia and a comparable SMO with purpose-built facilities and early-phase capabilities.
  • Nucleus Network: Australia's largest early-phase clinical trial organization with dedicated Phase I units in Melbourne and Brisbane; directly comparable to Emeritus for first-in-human, vaccine, and early-phase biotech trials targeting Australian sites.
  • CMAX Clinical Research: Adelaide-based Phase I-II clinical trial facility focused on early-phase and first-in-human studies; a regional Australian SMO competing for similar biotech and pharma sponsor workloads.
  • Paratus Clinical Research (formerly International Medical Research): Australian multi-site clinical research organization running Phase I-IV trials with sites across multiple states; an emerging peer scaling head-to-head with Emeritus for sponsor placements in dermatology, vaccines, and metabolic indications.

Others

  • Charles River Laboratories: Preclinical and early-phase clinical research services provider including early-phase site operations; comparable as an adjacent player that competes for early-phase sponsor budgets and influences site selection strategy.

Broad incumbents

  • ICON plc: Global CRO that owns dedicated clinical trial sites (e.g., PRA Health) and acts as a sponsor intermediary that books capacity at SMOs like Emeritus; comparable as a buyer-of-services and as a broader end-to-end alternative for sponsors.
  • IQVIA: World's largest CRO with embedded site network and site-management offerings; competes indirectly with Emeritus both as a buyer of SMO capacity in Australia and as an integrated alternative for sponsors.
  • Medpace: Mid-to-large global CRO with strong biotech sponsor relationships that frequently engage Australian SMOs; relevant comparable as a counterparty and as an integrated alternative to using a dedicated Australian SMO.
  • Thermo Fisher Scientific (PPD): Global CRO and clinical research services provider post-PPD acquisition; relevant as both a buyer of Emeritus's SMO capacity and as a broader competitive offering for sponsors running Australian trials.

Market position

Weaknesses1 record

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Emeritus Research social profiles

Digital presence

Emeritus Research financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Emeritus Research leadership team

Management profile

Number of profiles

Profiles16 records

Emeritus Research subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Emeritus Research funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Emeritus Research M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Emeritus Research

What does Emeritus Research do?

Emeritus Research is a private clinical trial site services organization that conducts Phase I-IV outpatient clinical trials for pharmaceutical sponsors and CROs across purpose-built facilities in Melbourne and Sydney, Australia. The company delivers full-service trial management, participant recruitment (via exclusive partnership with Clinibase), data management, and regulatory support across 30+ therapeutic areas including infectious disease, vaccines, obesity/metabolic diseases, rheumatology, cardiovascular, dermatology/immunology, neurology, and sexual health.

Is Emeritus Research a public or private company?

Emeritus Research is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Emeritus Research founded?

Emeritus Research was founded in 1999. It employs 101 to 250 people.

Where is Emeritus Research based?

Emeritus Research is headquartered in Camberwell, Australia, in the Oceania region.

How does Emeritus Research make money?

One revenue line is on record: clinical Trial Site Services.

Who are Emeritus Research's main competitors?

Direct peers on record are Q-Pharm, Linear Clinical Research, Nucleus Network, CMAX Clinical Research and Paratus Clinical Research (formerly International Medical Research). Charles River Laboratories is listed as an others. Broad incumbents are ICON plc, IQVIA, Medpace and Thermo Fisher Scientific (PPD).

Does Emeritus Research have an API?

No public API is recorded for Emeritus Research.

What industry is Emeritus Research in?

Emeritus Research's product category is Clinical Trial Site Services. Its primary akta.pro industry code is HLAGACAE, Clinical Trial Site Operations & Study Coordination, with a secondary code of HLAGACAG, Clinical Trial Monitoring Support (On-site/Remote). Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales